Search Results

There are 2087 results for: content related to: Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-IgE in Persistent Severe Allergic Asthma

    Allergy and Allergic Diseases, Volume 1, Second Edition

    Marc Humbert, Stephen T. Holgate, Howard Fox, Jean Bousquet, Pages: 1661–1686, 2009

    Published Online : 10 FEB 2009, DOI: 10.1002/9781444300918.ch81

  3. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

    Allergy

    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Article first published online : 24 APR 2015, DOI: 10.1111/all.12616

  4. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Article first published online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  5. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy

    Allergy

    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Article first published online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  6. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

    Allergy

    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Article first published online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  7. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment

    British Journal of Dermatology

    M.C. Urgert, M.T. van den Elzen, A.C. Knulst, Z. Fedorowicz and E.J. van Zuuren

    Article first published online : 22 JUL 2015, DOI: 10.1111/bjd.13845

  8. You have free access to this content
    Management and treatment of chronic urticaria (CU)

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue S3, June 2015, Pages: 16–32, M. Maurer, M.K. Church, M. Gonçalo, G. Sussman and M. Sánchez-Borges

    Article first published online : 4 JUN 2015, DOI: 10.1111/jdv.13198

  9. Omalizumab (Xolair): Anti-Immunoglobulin E Treatment in Allergic Diseases

    Handbook of Therapeutic Antibodies

    Claus Kroegel, Martin Foerster, Pages: 951–997, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch37

  10. Omalizumab may not inhibit mast cell and basophil activation in vitro

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 9, September 2015, Pages: 1832–1836, J. Gericke, T. Ohanyan, M.K. Church, M. Maurer and M. Metz

    Article first published online : 26 SEP 2014, DOI: 10.1111/jdv.12693

  11. Immunoglobulin E Blockade in the Treatment of Asthma

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 10, October 2007, Pages: 1412–1424, Robert Kuhn

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.27.10.1412

  12. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Article first published online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  13. You have free access to this content
    The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

    Allergy

    Volume 65, Issue 9, September 2010, Pages: 1141–1148, J. D. Campbell, D. E. Spackman and S. D. Sullivan

    Article first published online : 10 FEB 2010, DOI: 10.1111/j.1398-9995.2010.02336.x

  14. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Article first published online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  15. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Article first published online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x

  16. You have full text access to this OnlineOpen article
    Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

    Clinical & Experimental Allergy

    Volume 44, Issue 11, November 2014, Pages: 1371–1385, J. P. Arm, I. Bottoli, A. Skerjanec, D. Floch, A. Groenewegen, S. Maahs, C. E. Owen, I. Jones and P. J. Lowe

    Article first published online : 21 OCT 2014, DOI: 10.1111/cea.12400

  17. You have free access to this content
    Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

    Allergy

    Volume 66, Issue 5, May 2011, Pages: 671–678, J. Bousquet, Z. Siergiejko, E. Świebocka, M. Humbert, K. F. Rabe, N. Smith, J. Leo, C. Peckitt, R. Maykut and G. Peachey

    Article first published online : 21 JAN 2011, DOI: 10.1111/j.1398-9995.2010.02522.x

  18. You have free access to this content
    Effects of omalizumab on markers of inflammation in patients with allergic asthma

    Allergy

    Volume 64, Issue 12, December 2009, Pages: 1728–1736, S. Holgate, N. Smith, M. Massanari and P. Jimenez

    Article first published online : 15 OCT 2009, DOI: 10.1111/j.1398-9995.2009.02201.x

  19. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Article first published online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x

  20. You have free access to this content
    Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 61–76, Philip J. Lowe, Stacey Tannenbaum, Aurelie Gautier and Pablo Jimenez

    Article first published online : 26 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03401.x